This ruling has no material impact on Teva's stock. The underlying EpiPen antitrust MDL continues, but today's order is a routine discovery dispute over a non-party law firm's search terms and redactions. Monitor for substantive rulings on class certification, summary judgment, or trial, which would carry real financial exposure.
Price Chart
Executive Summary
A federal magistrate judge in Kansas granted in part and denied in part a motion to compel non-party law firm Goodwin Procter to re-run document searches in the long-running EpiPen antitrust MDL against Teva. The court denied plaintiffs' request for additional search terms as untimely and insufficiently justified, but ordered Goodwin to submit two redacted email strings for in camera review. This is a routine discovery dispute with no material financial exposure or business impact on Teva — the ruling does not address liability, damages, or any substantive claim in the underlying antitrust case.
Court Ruling Details
Key Facts
- Ruling is a discovery dispute over non-party law firm Goodwin Procter's document production in the EpiPen antitrust MDL (Case 2:22-cv-02501-DDC-TJJ).
- Court denied plaintiffs' request to compel Goodwin to run additional search terms, finding the motion untimely and the burden outweighed the likely benefit.
- Court granted in part plaintiffs' request regarding two redacted email strings, ordering Goodwin to submit unredacted versions for in camera review.
- No damages, injunction, or liability finding was made against Teva — the ruling concerns only procedural discovery obligations of a non-party law firm.
- The underlying case is a multi-district antitrust litigation regarding EpiPen pricing, but this specific ruling has no financial exposure for Teva.
Financial Impact
No financial impact — this is a procedural discovery ruling with no damages, penalties, or business restrictions imposed on Teva.
Risk Factors
- The underlying EpiPen antitrust MDL could eventually result in material damages or injunctive relief against Teva, but today's ruling does not change that risk profile.
- If the in camera review of the two email strings reveals discoverable material, it could lead to further discovery disputes, but the scope is narrow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-9d441e92f6-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access